|Summary sheet: 5-MeO-MiPT|
|Common names||5-MeO-MiPT, "Moxy"|
|Psychoactive class||Psychedelic / Entactogen|
|Routes of Administration|
5-Methoxy-N-methyl-N-isopropyltryptamine (also known as 5-MeO-MiPT and moxy) is a lesser-known psychedelic substance of the tryptamine class. 5-MeO-MiPT is chemically related to tryptamines like 5-MeO-DMT and 5-MeO-DiPT. It produces its psychoactive effects through activity at serotonin receptors in the brain.
The synthesis and pharmacology of 5-MeO-MiPT was first reported in 1985 by David Repke and Alexander Shulgin. Its effects in humans was documented in Shulgin's book TiHKAL ("Tryptamines I Have Known and Loved").
Anecdotal reports describe 5-MeO-MiPT's effects as highly stimulating and mildly entactogenic, lacking in typical psychedelic visual distortions. Many users report strong physical and tactile effects that serve to enhance libido and sexual pleasure. An unpleasant "body load" is also often reported at common to high doses, marked by muscle tension and nausea.
Very little is known about the pharmacological properties, metabolism and toxicity of 5-MeO-MiPT, and it has a limited history of human use. It has been sold online as a research chemical. It is highly advised to use harm reduction practices when using this substance.
- 1 Chemistry
- 2 Pharmacology
- 3 Subjective effects
- 4 Toxicity and harm potential
- 5 Legal status
- 6 See also
- 7 External links
- 8 References
5-MeO-MiPT, or 5-methoxy-N-methyl-N-isopropyltryptamine, is a synthetic indole alkaloid molecule of the tryptamine class. Tryptamines share a core structure comprised of a bicylic indole heterocycle attached at R3 to an amino group via an ethyl side chain. 5-MeO-MiPT is substituted at R5 of its indole heterocycle with a methoxy (MeO) functional group CH3O−; it also contains a methyl group and an isopropyl chain bound to the terminal amine RN of its tryptamine backbone (MiPT).
5-MeO-MiPT's psychedelic effects are believed to come from its efficacy at the 5-HT2A receptor as a partial agonist and additional mechanisms of action such as the inhibition of MAO (i.e. digestive enzymes in the stomach) have also been speculated upon, though this has yet to be demonstrated scientifically.
5-MeO-MiPT can be taken via oral ingestion or it can be smoked. When ingested orally, the visual and sensory effects are reported to become more prominent. The experience can be broken up into two stages; the first half feels stimulating and entactogenic whilst the second half feels more similar to a traditional tryptamine psychedelic like psilocybin mushrooms or LSD. When smoked, the physically and cognitively stimulating effects become emphasized.
The effects listed below are based upon the subjective effects index and personal experiences of PsychonautWiki contributors. These effects should be taken with a grain of salt and will rarely (if ever) occur all at once, but heavier doses will increase the chances of inducing a full range of effects. Likewise, adverse effects become much more likely on higher doses and may include serious injury or death.
- Stimulation - At doses below 10 to 15mg, 5-MeO-MiPT produces a degree of stimulation comparable to that of LSD.
- Spontaneous bodily sensations - The "body high" of 5-MeO-MiPT can be described as a pleasurable, warm, soft and all-encompassing glow. This may be accompanied by a cold, sharp tingling sensation that manifests spontaneously at different unpredictable points throughout the experience, although for others can maintain a consistent presence that steadily rises with the onset and hits its limit once the peak has been reached.
- Nausea - Nausea is commonly reported and can sometimes result in vomiting, although it typically fades after the come up phase. In comparison to 5-MeO-DiPT, this substance has a much lower tendency to trigger unpleasant physical reactions.
- Bodily pressures
- Abnormal heartbeat
- Increased heart rate
- Increased blood pressure
- Headaches
- Stomach bloating - At higher doses, this compound can induce severe stomach bloating within those who are susceptible. This can be partially to fully mitigated through the use of antacids.
- Pupil dilation
- Drifting (Melting, Breathing, Warping and Flowing) - In comparison to other psychedelics, this effect can be described as highly detailed, slow and smooth in motion and static in appearance.
- After images
- Symmetrical texture repetition
- Colour shifting
- Scenery slicing
The visual geometry produced by 5-MeO-MiPT can be described as more similar in appearance to that of Psilocin, 4-AcO-DMT or ayahuasca than that of LSD or 2C-B. It can be comprehensively described through its variations as intricate in complexity, abstract in form, organic in feel, brightly lit, multicoloured in scheme, glossy in shading, equal in blurred and sharp edges, large in size, fast in speed, smooth in motion, equal in rounded and angular corners, non-immersive in depth and progressive in intensity. At higher dosages they are significantly more likely to result in states of level 8B visual geometry over level 8A.
5-MeO-MiPT produces a full range of high level hallucinatory states in a fashion that is more consistent and reproducible than that of many other commonly used psychedelics.
- Internal hallucination (autonomous entities; settings, sceneries, and landscapes; perspective hallucinations and scenarios and plots) - In comparison to other psychedelics such as LSD, 5-MeO-MiPT is extremely high in hallucinations at appropriate dosages. These are more common in darkness and can be comprehensibly described through their variations as lucid in believability, interactive in style, new experiences in content, autonomous in controllability, geometry-based in style and almost exclusively of a personal, religious, spiritual, science-fiction, fantasy, surreal, nonsensical or transcendental nature in their overall theme.
At low to moderate doses, the cognitive effects of 5-MeO-MiPT are often described by many as both insightful and moderately relaxing, but at some points quite stimulating. 5-MeO-MiPT produces a large number of typical psychedelic cognitive effects which progressively intensify proportional to dosage. At higher dosages, however, it becomes primarily sedating and impairing with depersonalization and no accompanying insight.
- Analysis enhancement
- Empathy, affection, and sociability enhancement - This effect is consistently manifested only in the context of social settings in which one is within the company of others. These feelings of sociability, love and empathy are a little weaker and less sharp than those found on substances such as MDMA and 2C-B but still prove strong enough to provide long-lasting therapeutic effects.
- Depersonalization - Unlike most traditional psychedelics, 5-MeO-MiPT can cause extreme depersonalization and dissociation for some users throughout the duration of the experience.
- Conceptual thinking
- Increased music appreciation
- Emotion enhancement
- Increased libido
- Memory suppression
- Novelty enhancement
- Personal bias suppression
- Thought acceleration
- Thought connectivity
- Time distortion
There are currently no anecdotal reports which describe the effects of this compound within our experience index. Additional experience reports can be found here:
Toxicity and harm potential
The toxicity and long-term health effects of recreational 5-MeO-MiPT do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because 5-MeO-MiPT is a research chemical with very little history of human usage.
Anecdotal evidence from people within the community who have tried 5-MeO-MiPT suggests that there are no negative health effects attributed to simply trying the drug by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.
It is strongly recommended that one use harm reduction practices when using this drug.
Tolerance and addiction potential
5-MeO-MiPT is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating.
Tolerance to the effects of 5-MeO-MiPT are built almost immediately after ingestion. After that, it takes about 3 days for the tolerance to be reduced to half and 7 days to be back at baseline (in the absence of further consumption). 5-MeO-MiPT presents cross-tolerance with all psychedelics, meaning that after the consumption of 5-MeO-MiPT all psychedelics will have a reduced effect.
Although many psychoactive substances are safe to use on their own, they can quickly become dangerous or even life-threatening when combined with other substances. The following lists some known dangerous combinations, but may not include all of them. A combination that appears to be safe in low doses can still increase the risk of injury or death. Independent research should always be conducted to ensure that a combination of two or more substances is safe to consume.
- Tramadol - Tramadol lowers the seizure threshold and psychedelics may act as triggers for seizures, particularly in those who are predisposed to them.
- Stimulants - Stimulants affect many parts of the brain. Combined with psychedelics, stimulation can turn into uncontrollable anxiety, panic, thought loops and paranoia. This interaction may cause elevated risk of psychosis.
- Lithium - Lithium is often used as treatment for bipolar disorder. It may possibly cause elevated risk of seizures and psychosis due to its glutaminergic and GABAergic effects.
There are no known deaths from 5-MeO-MiPT but, as a monoamine reuptake inhibitor (MRI), injury could occur when excessive doses are taken or when it is taken with drugs such as MAOIs, RIMAs, stimulants and any substance which act as a releasing agent or reuptake inhibitor of neurotransmitters such as serotonin and dopamine.
- Brazil: 5-MeO-MiPT is illegal to produce, sell, or possess as it is listed on Portaria SVS/MS nº 344.
- China: 5-MeO-MiPT is controlled as a Category I psychotropic substance and is illegal to sell, buy, import, export, and manufacture.
- Finland: 5-MeO-MiPT was banned in Finland in December 2014.
- Japan: 5-MeO-MiPT is controlled as a "Designated Substance" (Shitei-Yakubutsu) by the Pharmaceutical Affairs Law, making it illegal to possess or sell.
- Latvia: 5-MeO-MiPT is a Schedule I drug in Latvia.
- New Zealand: 5-MeO-MiPT is an analogue of DMT which makes it a Class C controlled drug in New Zealand.
- Romania: 5-MeO-MiPT and other derivatives are illegal in Romania, as of January 2011.
- United Kingdom: 5-MeO-MiPT is a Class A drug in the UK as it is an ether of the drug 5-HO-MiPT, which is a Class A drug as a result of the tryptamine catch-all clause.
- United States: 5-MeO-MiPT is unscheduled in the United States. It may be considered an analogue of 5-MeO-DiPT, a Schedule I drug under the Controlled Substances Act. As such, the sale for human consumption or the use for illicit non-medical or industrial intents and purposes could be prosecuted as crimes under the Federal Analogue Act.
- Repke, D. B., Grotjahn, D. B., & Shulgin, A. T. (1985). Psychotomimetic N-methyl-N-isopropyltryptamines. Effects of variation of aromatic oxygen substituents. Journal of medicinal chemistry, 28(7), 892-896. PMID: 4009612
- The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain (ScienceDirect) | http://www.sciencedirect.com/science/article/pii/S0014299906013811
- Psychotomimetic N-methyl-N-isopropyltryptamines. Effects of variation of aromatic oxygen substituents | http://pubs.acs.org/doi/abs/10.1021/jm00145a007
- Talaie, H., Panahandeh, R., Fayaznouri, M. R., Asadi, Z., & Abdollahi, M. (2009). Dose-independent occurrence of seizure with tramadol. Journal of medical toxicology, 5(2), 63-67. doi:10.1007/BF03161089
- The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain. (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/17223101
- Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity | http://bja.oxfordjournals.org/content/95/4/434
- Erowid China Psychoactive Law Update: September 2015 | https://www.erowid.org/psychoactives/law/countries/china/china_law_2015_09_27_list_of_newly_controlled_chemicals.pdf
- Finland's Prohibited Psychoactive Substances: December 19, 2014. https://www.erowid.org/psychoactives/law/countries/finland/finland_law1_2014.pdf
- Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem (Triptamīni) | http://likumi.lv/doc.php?id=121086
- Misuse of Drugs Act 1971 (Legislation.gov.uk) | http://www.legislation.gov.uk/ukpga/1971/38/schedule/2/part/I/paragraph/3
- Misuse of Drugs Act 1971 (Legislation.gov.uk) |http://www.legislation.gov.uk/ukpga/1971/38/schedule/2/part/I#reference-M_F_c7632653-ddad-4420-f307-e3da1e36d30e
- The 2015 Florida Statutes - Title XLVI CRIMES - Chapter 893 - DRUG ABUSE PREVENTION AND CONTROL | http://www.leg.state.fl.us/Statutes/index.cfm?App_mode=Display_Statute&URL=0800-0899/0893/Sections/0893.03.html
- 5-MeO-MiPT Legal Status by Erowid | https://www.erowid.org/chemicals/5meo_mipt/5meo_mipt_law.shtml
- 2015 Minnesota Statutes | https://www.revisor.mn.gov/statutes/?id=152.02